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Synovial Sarcoma is a malignant mesenchymal tumor that comprises 5–10% of all soft tissue sarcomas. The mean age of onset
is thirty years old. Intraosseous presentation is very rare and has only been documented a few times. We report herein a case of
a 53-year-old man with synovial sarcoma arising in the left proximal tibia. The patient underwent a wide surgical resection and
reconstruction, followed by adjuvant chemotherapy. Three years later, the patient developed a local recurrence that resulted in an
above-the-knee amputation. Eight months later, the patient has completed chemotherapy and is without signs of recurrence. The
current recommended treatment for synovial sarcoma is wide surgical resection followed by chemotherapy as well as long-term
followup. Despite improved surgical techniques, long-term survival rates remain low.
1.Introduction
Synovial sarcoma usually arises in the soft tissues of the
extremities and rarely presents as a primary bone tumor.
The ﬁrst reported case of an intraosseous synovial sarcoma
occurred in the proximal tibia [1]. Since then, only two
cases have been completely documented with histological
and molecular genetic conﬁrmation [2, 3]. Five additional
incompletely documented cases have been reported [4–
8].
Synovial sarcoma is a malignant soft tissue tumor that
c omprises5–10%ofallsofttissuesar c omas[3].Itmostoften
aﬀects adolescents and young adults and has a mean age of
onset of 30 years [9], with less than 10% of patients being
over the age of 60 [10].
It usually arises in the lower extremities [4]. The large
majority of tumors appear near large joints, but it has also
been reported to arise in a variety of other locations such
as in the head and neck [11], chest [12], and abdomen
[13]. While 20% show erosion or invasion of adjacent bone
[14], primary synovial sarcoma of bone is extremely rare [3].
We report a case of primary intraosseous synovial sarcoma
arising in the proximal tibia.
2.CaseReport
A 53-year-old man presented with a 3-month history of left
knee pain. He had diﬃculty weight bearing and complained
of swelling of the calf as well as a lack of sensation in the
toes.X-raysshowedalarge,5cmroundlucencyinvolvingthe
lateral proximal portion of the tibia (Figure 1(a)). The lateral
view showed stippled mineralization extending into the soft
tissues posteriorly (Figure 1(b)). MRI showed a large mass in
the tibial plateau of the left proximal tibia with a soft tissue
extension postero-laterally.
Chest X-ray was negative for metastatic disease. A CT
scanofthechest,pelvis,andabdomenalongwithabonescan
were negative except for an increased uptake in the proximal
tibia. A core needle biopsy was performed revealing a high-
grade sarcoma. A proximal tibial resection with negative
margins was performed. Grossly, the tumor was tan-yellow,
arising in the proximal tibia and extending into the adjacent
softtissue.Theintraosseouscomponentmeasured6.0×5.0×
3.5cm and the extraosseous soft tissue component measured
4.0×3.0×2.0cm(Figure 2).Histologically,thetumorshowed
the characteristic features of a biphasic synovial sarcoma,
containing obvious glandular diﬀerentiation admixed with2 International Journal of Surgical Oncology
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Figure 1: (a) A/p radiograph of the left knee shows a round lucency at the lateral tibial plateau with well-deﬁned proximal margins and
a less well-deﬁned distal margin.(b) Lateral radiograph shows a stippled mineralization (arrow) projecting into the soft tissues posteriorly,
measuring approximately 2.5cm in maximal diameter.
Figure 2: Grossly the tumor is eccentrically located in the proximal
tibia. It has a tan-grey ﬂeshy cut surface, which breaks through the
cortex and extends into adjacent soft tissue (right).
a malignant spindle cell component (Figures 3(a) and 3(b)).
Immunohistochemical studies showed that the neoplastic
cells were positive for keratin, cytokeratin 7, and epithelial
membrane antigen (EMA). Fluorescence in situ hybridiza-
tion (FISH) analysis was performed on interphase nuclei
isolated from f paraﬃn-embedded 50µmt i s s u es e c t i o n s ,
for the detection of possible t(X;18)(p11;q11). An SS18
rearrangement was observed in 49/50 nuclei examined,
conﬁrming the diagnosis of synovial sarcoma (Figure 4).
An endoprosthetic reconstruction was performed using a
cemented prosthesis (Figures 5(a) and 5(b)). The patient was
treated with adjuvant chemotherapy including dacarbazine,
doxorubicin, ifosfamide, and mesna.
Three years later, the patient presented again with left
knee pain. A PET/CT scan revealed multiple soft tissue
nodules above and below the knee (Figures 6(a) and
6(b)). A CT scan of the chest was negative. A ﬁne needle
aspiration revealed recurrent synovial sarcoma. The patient
underwent an above-the-knee amputation with prosthetic
reconstruction.
The resection specimen showed soft tissue nodules above
and below the knee with a large soft tissue component as
well as involvement of the distal femur. The tumor measured
4 × 3 × 2.5cm in its largest dimension. Again, the tumor
was noted to be biphasic synovial sarcoma. The patient
was restarted on adjuvant chemotherapy including mesna,
adriamycin, ifosfamide, and dacarbazine. Eight months
have passed since the amputation. He continues adjuvant
chemotherapy and has no other sites of disease.
3. Discussion
Synovial sarcoma was originally named in 1936 by Knox as
it was believed to be of synovial cell origin [3]. This term
is misleading as many cases of synovial sarcoma have been
found to originate elsewhere where no synovial tissue is
present,andatthistime,thetumorisregardedasaneoplasm
of “uncertain histogenesis” [15]. Many cases occur outside of
the synovium and less than 5% of synovial sarcomas actually
originate in a joint or bursa [14]. While 20% of synovial
sarcomas show invasion of local bone, it is extremely rare for
it to present as a primary bone tumor [14].International Journal of Surgical Oncology 3
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Figure 3: (a) Photomicrograph of intraosseous synovial sarcoma. The tumor is present in the medullary cavity of the bone (left), inﬁltrates
the cortex, and expands the haversian systems. (Stain, hematoxylin, and eosin; original magniﬁcation, ×40). (b) Photomicrograph of
intraosseous synovial sarcoma. The tumor shows a typical biphasic pattern with glandular diﬀerentiation admixed with spindle-shaped
cells. (Stain, hematoxylin, and eosin; original magniﬁcation, ×400).
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Figure 4: Interphase nuclei showing an abnormal hybridiza-
tion pattern using the Vysis LSI SS18 Dual Color, Break Apart
Rearrangement Probe at 18q11.2 (Abbott Molecular). SS18 gene
rearrangementappearedasaseparationofthered-orangeandgreen
signals from the normal fusion signal (yellow).
Webelievethatourcaserepresentsaprimarybonetumor
because the osseous extent of the tumor is greater than
the soft tissue component. In addition, our imaging studies
suggest that the epicenter of the tumor began in bone and
grew secondarily into soft tissues.
Radiographically, synovial sarcoma presents with MR
ﬁndings of heterogeneous intermediate signal intensity on
T1W1,heterogeneoushighsignalintensityonfat-suppressed
T2W1, and heterogeneous contrast enhancement [3]. Histo-
logically,synovialsarcomaisclassiﬁedasbiphasic,monopha-
sic, or poorly diﬀerentiated [15], with the biphasic being
the most common. Synovial sarcoma is locally aggressive,
and distant metastases are common [9]. Additionally the
diagnosis of synovial sarcoma can be conﬁrmed genetically
with the detection of t(X;18)(p11.2;q11.2). This transloca-
tion involves the SS18 (a.k.a.SYT) gene on chromosome 18
and either the SSX1, SSX2, or rarely the SSX4 gene on the
X chromosome [15]. This translocation occurs in more than
9 0 %o fa l ls y n o v i a ls a r c o m a s[ 10].
Synovial sarcoma of bone was ﬁrst reported in 1997 [1].
Since then conﬁrmed cases of primary synovial sarcoma of
bone have been found in the sacrum [6], distal tibia [7],
mandible [8], elbow [2, 4], distal tibia [3], and sternum
[5]. Due to its aggressive nature, recommended treatment
is a combination of wide surgical resection to achieve
clear margins, followed by chemotherapy and/or irradiation.
Long-term follow-up is necessary due to this tumor’s high
rate of recurrence and metastasis [16].
Development of distant metastasis and decreased
disease-speciﬁc survival has been correlated to a large
tumor size (greater than 5cm) and invasion of bone, nerve,
or vascular structures [16, 17]. In 1950, a study of 60
patients treated only with simple excision showed a 63%
l o c a lr e c u r r e n c er a t e[ 18]. As a result of this study, simple
excision as the solitary form of treatment is no longer being
practiced.
Studies have shown clear indications for the use of
irradiation therapy for local control of synovial sarcoma. In
2000, Lewis et al. showed a local recurrence of only 10% in
their series of 112 patients with primary localized tumors of
the extremity [17]. Approximately half of the patients in this
study also underwent adjuvant irradiation. The authors thus
attributed this better local recurrence rate, in comparison to
the 1950 study, to improved surgical techniques as well as to
the use of adjuvant radiation [17].
While the rate of local recurrence has diminished, the
rate of distant metastasis is still a challenge for clinicians.
Lewis et al. found a 40% chance of metastasis within ﬁve
years, despite wide surgical resection with negative margins
[17]. Five-year survival rate has been reported to be as low
as 25–50%, while ten-year survival rate is only 10–15% [8].
While the use of chemotherapy for systemic control has
been previously questioned, a recent study has shown that
chemotherapy treatment is signiﬁcantly associated with an
increased 4-year disease-speciﬁc survival (DSS) [16]. The
4-year DSS was 88% in the ifosfamide- treated patients4 International Journal of Surgical Oncology
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Figure 5: Postoperative anterior posterior, (a) and lateral (b) radiographs o ft h el e f tk n e ed e m o n s t r a t et h ee n d o p r o s t h e t i cr e c o n s t r u c t i o no f
the proximal tibia and knee joint.
(a) (b)
Figure 6: (a) A preoperative CT scan reveals multiple soft tissue nodules (arrow) above and below the knee including areas medial, lateral,
anterior, posterior and in the suprapatellar recess. (b) A preoperative PET scan shows intense FDG uptake in the multiple soft tissue nodules
above and below the knee consistent with recurrent disease.
and 67% in the patients that did not receive chemotherapy
[16].
We chose chemotherapy treatment over radiation fol-
lowing surgical resection in order to decrease the chance
of distant metastasis. The primary tumor, being larger than
5cm, had an increased chance of distant metastasis [17].
There was also a signiﬁcant soft tissue component. The
recurrent tumor displayed multiple soft tissue nodules that
indicated it was at least a regional, if not a systemic problem
that would also increase the chance for metastasis.
Overall, these recent studies are showing a positive
progression of treatment methods. The lower rates of local
recurrence are promising, but the low ﬁve-year survival rates
and the high chance of distant metastasis still show the need
for the development of adequate systemic therapy. Due to
the aggressive nature of this disease and the high rate of
metastasis, long-term follow-up is essential.
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